Exclusive Summary

• - Patents expired long ago and generics are fully entrenched; 500 mg/5 mL IV is a mature high‑volume hospital emergency product.
• - Around 50 million people live with epilepsy globally, with 0.8–1.6 million status epilepticus cases annually driving IV demand across adult and pediatric care.
• - Listed on WHO EML and recommended by multiple guidelines as a second‑line IV option after benzodiazepines, with safety advantages over phenytoin/phenobarbital and easy IV‑to‑oral transition.
• - Already registered in the US and EU27, ensuring high compliance and enabling faster reliance approvals and tender participation in new markets.
• - Delivers 70–90% cost savings versus originator, aligning with DRG/budget constraints and hospital cost‑containment.